# An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

> **NCT06281847** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Advesya SAS** · enrollment: 143 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory

## Interventions

- **GENETIC:** CCTx-001

## Key facts

- **NCT ID:** NCT06281847
- **Lead sponsor:** Advesya SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-07
- **Final completion:** 2041-08
- **Target enrollment:** 143 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281847, "An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06281847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*